BioAtla Secures $5 Million for Oz-V Phase 3 Clinical Trial Expenses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Funding Support: BioAtla secures an initial $5 million through a SPV transaction with GATC Health for Oz-V's operational and clinical trial expenses, with an additional $35 million expected to close in Q1 2026, ensuring progress in the 2L+ OPSCC development.
- Equity Structure: After the SPV transaction, BioAtla will retain 65% ownership of Oz-V, maintaining its leading position across all solid tumor indications, while Inversagen AI will acquire a 35% stake, fostering collaborative research on age-related diseases.
- Clinical Trial Plans: BioAtla will lead the Phase 3 trial for Oz-V in OPSCC, with enrollment anticipated to begin in early 2026, paving the way for potential accelerated approval and significantly enhancing the company's competitiveness in the oncology market.
- Market Potential: Targeting the ROR2 receptor, Oz-V has the potential to expand into HPV-positive tumors, representing a market opportunity exceeding $7 billion, while BioAtla's CAB platform technology is poised to play a crucial role in treating age-related diseases, further solidifying its market position.
Analyst Views on BCAB
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.784
Low
10.00
Averages
10.00
High
10.00
Current: 0.784
Low
10.00
Averages
10.00
High
10.00
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
